Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07195682 · ClinicalTrials.gov registry record · Phase 1
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
A Phase 1 study of Renal Cell Carcinoma, sponsored by Bristol-Myers Squibb.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 125
- Enrollment target
- 9
- Study locations
NCT07195682 is a Phase 1 study of Renal Cell Carcinoma that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 125 participants, below the 242-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (48% lower). The trial reports 9 study locations across 9 states.
The verdict
NCT07195682, a Phase 1 study of Renal Cell Carcinoma, is actively recruiting participants, sponsored by Bristol-Myers Squibb.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 125 participants
- Enrollment target
- 9
- Study locations
Study Summary
This is a first-in-human study of BMS-986506 in participants with advanced Clear Cell Renal Cell Carcinoma (ccRCC). The primary objective of this study is to find out if BMS-986506 is safe and can be tolerated when taken alone by participants with ccRCC.
Conditions Studied
Interventions
- DRUG BMS-986506
Study Locations (9)
Massachusetts
- Local Institution - 0006 - Boston
New York
- Memorial Sloan Kettering Cancer Center - New York
Pennsylvania
- Local Institution - 0002 - Philadelphia
Tennessee
- SCRI Oncology Partners - Nashville
Texas
- START San Antonio - San Antonio
Alberta
- Arthur J.E. Child Comprehensive Cancer Centre - Calgary
Val-de-Marne
- Local Institution - 0008 - Villejuif
Andalusia
- Local Institution - 0015 - Córdoba
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2026-01-15 |
| Est. Completion | 2031-04-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07195682
The ClinicalTrials.gov registry entry for NCT07195682 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 242-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (48% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which BMS-986506 is the first listed.
NCT07195682 reports 9 study locations spanning 9 distinct geographic areas - top geographies include Massachusetts, New York, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT07195682 about?
NCT07195682 is a clinical study titled "A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)". This is a first-in-human study of BMS-986506 in participants with advanced Clear Cell Renal Cell Carcinoma (ccRCC). The primary objective of this study is to find out if BMS-986506 is safe and can be tolerated when taken alone by participants with ccRCC.
What is the current status of trial NCT07195682?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 125 participants. The study started on 2026-01-15. Estimated completion is 2031-04-03.
What conditions does trial NCT07195682 study?
This clinical trial studies the following conditions: Renal Cell Carcinoma.
What interventions are being tested in trial NCT07195682?
The interventions under investigation include: BMS-986506 (DRUG).
Who is sponsoring clinical trial NCT07195682?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07195682 being conducted?
This trial has 9 study locations across Massachusetts, New York, Pennsylvania, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
RECRUITING · Phase 1
-
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
RECRUITING · Phase 1
-
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
RECRUITING · Phase 1
-
[18F]PT2385 PET/CT in Patients With Renal Cell Carcinoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.